Monoclonal antibodies against human bit1, an apoptosis-associated mitochondrial protein

Wei Hua1, Biliang Chen, Wei Zhang

  • 1Department of Obstetrics and Gynecology, Xijing Hospital, The Fourth Military Medical University, Xi'an, P.R. China.

Hybridoma (2005)
|June 13, 2009
PubMed

Insights

Researchers developed monoclonal antibodies (MAbs) targeting Bcl2-inhibitor of transcription 1 (Bit1). These antibodies are valuable for studying ovarian cancer apoptosis and monitoring patient data.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Bcl2-inhibitor of transcription 1 (Bit1) is a mitochondrial protein.
  • Bit1 induces caspase-independent apoptosis upon cytoplasmic release.
  • Bit1 interacts with amino-terminal enhancer of split (AES) in the cytoplasm.

Purpose of the Study:

  • To develop monoclonal antibodies (MAbs) against human Bit1.
  • To characterize the generated MAbs and their epitopes.
  • To establish a method for detecting serum Bit1 levels and assess its clinical relevance in ovarian cancer.

Main Methods:

  • Murine hybridoma technique was employed to generate MAbs against Bit1.
  • Recombinant Bit1-His protein and cytosolic fractions of ovarian cancer cells were used.
  • MAbs were characterized using indirect ELISA, Western blotting, and immunohistochemistry.
  • A sandwich assay was developed for serum Bit1 detection.

Main Results:

  • Two hybridoma cell lines secreting MAbs against Bit1 were successfully established.
  • The MAbs were confirmed to recognize distinct epitopes on Bit1.
  • A significant difference in serum Bit1 levels was observed between ovarian carcinoma patients and healthy controls.
  • The sandwich assay demonstrated effectiveness in detecting serum Bit1.

Conclusions:

  • The developed MAbs against human Bit1 show promise for investigating tumor apoptosis mechanisms.
  • These MAbs could serve as a tool for monitoring clinical data in ovarian cancer patients.
  • Further research utilizing these MAbs may enhance understanding and management of ovarian cancer.